TABLA
Financiado
Development and Commercialisation of Transbronchial Lung Ablation to Treat Lung...
Lung cancer is the most common cause of cancer deaths in the EU and worldwide with more than 0.4M people diagnosed
each year. It has a dismal 5 year survival rate of just 18% and worldwide someone dies of lung cancer every 30 seco...
Lung cancer is the most common cause of cancer deaths in the EU and worldwide with more than 0.4M people diagnosed
each year. It has a dismal 5 year survival rate of just 18% and worldwide someone dies of lung cancer every 30 seconds.
The impact of the disease on public health is substantial with > 6M hospital admissions in Europe each year (>€18 billion in
economic costs). Surgery has been shown to provide a curative solution, but only 20-30% of patients can undergo surgery
due to co-morbidities.
Endowave have developed a pioneering device, designed to destroy the targeted tumour in a single, minimally invasive
intervention. The patented technology uses a flexible catheter system, that can be navigated through the patient’s airway to
deliver targeted microwave heating to the tumour. This will enable physicians provide a curative treatment that can be
delivered in an outpatient setting, improving patient outcomes and reducing costs to healthcare system.
The global market opportunity for lung cancer exceeds €3.6 billion. Endowave has formed a consortium of leading
companies that seeks to commercial Endowave’s technology and capture this market opportunity. The proposal is seeking
funding to complete the final development of the microwave system, carry out clinical studies achieve regulatory approval.
This will enable Endowave to enter the market, where we forecast revenues of €60 million by Year 5 based on conservative
market penetration forecasts. This project will drive job generation in Endowave and consortium partners as sales volumes
increase.
ver más
Duración del proyecto: 38 meses
Fecha Inicio: 2020-03-26
Fecha Fin: 2023-05-31
Fecha Fin: 2023-05-31
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2023-05-31
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
EIC-FTI-2018-2020:
Fast Track to Innovation (FTI)
Cerrada
hace 6 años
Presupuesto
El presupuesto total del proyecto asciende a
4M€
Líder del proyecto
ENDOWAVE LIMITED
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
343.71K€ |
Participante